Brought to you by 
RPR licenses Enzon's Oncaspar for cancer
05 May 2006
Executive Summary
Rhone-Poulenc Rorer is licensing the exclusive right to develop and market Enzon's cancer drug Oncaspar (PEG-modified L-asparaginase enzyme, or pegaspargase) in the US and Canada. Oncaspar is native L-asparaginase modified with Enzon's Pegnology, a delivery technology that attaches strands of polyethylene glycol to the drug to overcome the hypersensitivity problem. PEG-modification disguises the agent from potential attack by the immune system and extends the drug's half-life of circulation in the body--Oncaspar has to be injected only once every two weeks.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
RPR licenses Enzon's Oncaspar for cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice